The Food and Drug Administration has approved Cipla’s difluprednate ophthalmic emulsion 0.05%.
The medication is the generic of Novartis’ Durezol.
It is used for the treatment of inflammation and pain associated with ocular surgery, and for the treatment of endogenous anterior uveitis.
Durezol had a market value of approximately $106 million for the 12-month period ended June 2021, according to IQVIA.
Cipla’s product will be available for shipping soon.